Needham & Company LLC Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock Price

Lucid Diagnostics (NASDAQ:LUCD) had its price objective boosted by Needham & Company LLC from $2.50 to $3.00 in a report published on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Ascendiant Capital Markets reduced their price objective on shares of Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating on the stock in a research report on Monday, December 9th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $3.75.

Lucid Diagnostics Stock Performance

Shares of LUCD stock opened at $1.50 on Monday. The firm has a market cap of $89.01 million, a P/E ratio of -1.32 and a beta of 1.34. The business’s 50 day moving average price is $1.21 and its 200-day moving average price is $0.99. Lucid Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $1.63.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in LUCD. LPL Financial LLC grew its stake in Lucid Diagnostics by 29.1% in the fourth quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock worth $44,000 after purchasing an additional 12,035 shares during the period. Sunbelt Securities Inc. bought a new stake in shares of Lucid Diagnostics during the 4th quarter valued at $67,000. Citadel Advisors LLC bought a new stake in shares of Lucid Diagnostics during the 4th quarter valued at $98,000. Lido Advisors LLC grew its position in shares of Lucid Diagnostics by 40.0% in the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock worth $115,000 after buying an additional 40,000 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Lucid Diagnostics by 30.9% in the 4th quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock worth $229,000 after acquiring an additional 65,964 shares in the last quarter. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.